PolyPid Ltd. (NASDAQ:PYPD) Receives Average Rating of "Buy" from Brokerages

Key Points

• PolyPid Ltd. has received an average rating of "Buy" from six research firms, with five analysts ranking it as a buy and one as a strong buy.
• The stock has an average one-year price target of $12.40, although recent price targets have been adjusted downwards by several analysts.
• PolyPid's quarterly earnings report showed a loss of ($0.78) EPS, missing the consensus estimate of ($0.53), which could affect investor sentiment.

PolyPid Ltd. (NASDAQ:PYPD - Get Free Report) has received an average rating of "Buy" from the six research firms that are presently covering the stock, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $12.40.

Several research analysts have recently issued reports on the company. Roth Capital restated a "buy" rating on shares of PolyPid in a research note on Thursday, August 14th. JMP Securities reduced their price objective on PolyPid from $16.00 to $14.00 and set a "market outperform" rating for the company in a research note on Tuesday, June 17th. Craig Hallum reiterated a "buy" rating and set a $13.00 price target (down from $15.00) on shares of PolyPid in a research report on Thursday, August 14th. HC Wainwright reiterated a "buy" rating and set a $13.00 price target on shares of PolyPid in a research report on Wednesday, August 13th. Finally, Wall Street Zen cut PolyPid from a "hold" rating to a "sell" rating in a research report on Saturday, August 16th.

PolyPid Stock Performance

Shares of NASDAQ PYPD opened at $3.35 on Friday. PolyPid has a fifty-two week low of $2.30 and a fifty-two week high of $3.93. The company has a market cap of $53.27 million, a PE ratio of -0.87 and a beta of 1.40. The business has a 50-day simple moving average of $3.50 and a two-hundred day simple moving average of $3.09.

PolyPid (NASDAQ:PYPD - Get Free Report) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.25). On average, sell-side analysts predict that PolyPid will post -1.79 earnings per share for the current fiscal year.

Institutional Trading of PolyPid

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Lumbard & Kellner LLC purchased a new stake in shares of PolyPid in the second quarter valued at approximately $135,000. AIGH Capital Management LLC increased its position in shares of PolyPid by 27.0% in the second quarter. AIGH Capital Management LLC now owns 1,194,108 shares of the company's stock valued at $4,215,000 after buying an additional 253,727 shares in the last quarter. Finally, J. Goldman & Co LP purchased a new stake in shares of PolyPid in the fourth quarter valued at approximately $391,000. 26.47% of the stock is currently owned by hedge funds and other institutional investors.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.